First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC

被引：72

作者：

Kawamura, Y

Fujiwara, H

Mishima, N

Tanaka, Y

Tanimoto, A

Ilawa, S

Itoh, Y

Ezaki, T

机构：

[1] Gifu Univ, Grad Sch Med, Dept Microbial Bioinformat Regenerat & Adv Med Sc, Gifu 5008705, Japan

[2] Tottori Univ, Fac Med, Dept Pathophysiol & Therapeut Sci, Div Clin Lab Med, Yonago, Tottori 6838504, Japan

[3] Tottori Univ Hosp, Dept Clin Labs, Yonago, Tottori 6838504, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 11期

关键词：

D O I：

10.1128/AAC.47.11.3605-3609.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Three isolates of Streptococcus agalactiae highly resistant to multiple fluoroquinolones were isolated in Japan. Compared with susceptible strains of S. agalactiae, these quinolone-resistant strains had double point mutations within the quinolone resistance-determining regions of gyrA and parC; Ser-81 was changed to Leu (TCA --> TTA) in the amino acid sequence deduced from gyrA, and Ser-79 was changed to Phe (TCC --> TTC) in the amino acid sequence deduced from parC. Comparative sequence analysis revealed the possibility of gene transfer between S. agalactiae and another beta-hemolytic streptococcus, Streptococcus difficile.

引用

收藏

页码：3605 / 3609

页数：5

相关论文

共 17 条

[1] Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 [J].

Brueggemann, AB ;

Coffman, SL ;

Rhomberg, P ;

Huynh, H ;

Almer, L ;

Nilius, A ;

Flamm, R ;

Doern, GV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :680-688

[2]

HARDIE JM, 1995, GENERA LACTIC ACID B, P55

[3] Fluoropuinolone resistance among Gram-positive cocci [J].

Hooper, DC .

LANCET INFECTIOUS DISEASES, 2002, 2 (09) :530-538

[4] High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA [J].

Janoir, C ;

Zeller, V ;

Kitzis, MD ;

Moreau, NJ ;

Gutmann, L .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2760-2764

[5] Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae [J].

Jorgensen, JH ;

Weigel, LM ;

Swenson, JM ;

Whitney, CG ;

Ferraro, MJ ;

Tenover, FC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :2962-2968

[6] Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci [J].

Jorgensen, JH ;

Weigel, LM ;

Ferraro, MJ ;

Swenson, JM ;

Tenover, FC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :329-334

[7] DETERMINATION OF 16S RIBOSOMAL-RNA SEQUENCES OF STREPTOCOCCUS-MITIS AND STREPTOCOCCUS-GORDONII AND PHYLOGENETIC-RELATIONSHIPS AMONG MEMBERS OF THE GENUS STREPTOCOCCUS [J].

KAWAMURA, Y ;

HOU, XG ;

SULTANA, F ;

MIURA, H ;

EZAKI, T .

INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1995, 45 (02) :406-408

[8]

LEVEN M, 2000, J ANTIMICROB CHEM S1, V45, P51

[9] Change of antimicrobial susceptibility of group B streptococci over 15 years in Japan [J].

Matsubara, K ;

Nishiyama, Y ;

Katayama, K ;

Yamamoto, G ;

Sugiyama, M ;

Murai, T ;

Baba, K .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :579-582

[10] ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype [J].

Munoz, R ;

DelaCampa, AG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2252-2257